Investigational Drug Steering Committee

The NCI Investigational Drug Steering Committee (IDSC) was established in November 2005. The IDSC is composed of the Steering Committee, ten task forces, and three working groups. Members of the IDSC include the principal investigators of NCI's early drug development grants and contracts, representatives from the Cooperative Groups, a patient advocate, biostatisticians, and NCI staff.

Mission Statement

The IDSC provides NCI with broad external scientific and clinical input on the design and prioritization of phase I and phase II trials with agents for which Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application. The IDSC aims to increase the predictive value of early phase trials, resulting in the design of more successful phase III trials.

Roster of Investigational Drug Steering Committee (IDSC) members
Charles Erlichman, M.D. and Michael Grever, M.D., Co-chairs

Task Forces

• Angiogenesis: George Wilding, M.D. and Roy Herbst, M.D., Ph.D., Co-chairs
• Biomarkers: Walter Stadler, M.D. and Janet Dancey, M.D., Co-chairs
• Cancer Stem Cell Therapeutics: Patricia LoRusso, D.O., Lucio Miele, M.D. and William Matsui, M.D., Co-chairs
• Clinical Trial Design: Lesley Seymour, M.D., Ph.D. and Donald Berry, Ph.D., Co-chairs
• DNA Repair and Programmed Cell Death: Robert DiPaola, M.D. and Miguel Villalona, M.D., Co-chairs
• Gap Analysis: Donald Kufe, M.D. and Edward A. Sausville, M.D., Ph.D., Co-chairs
• Immunotherapy: Mario Sznol, M.D. and Thomas Gajewski, M.D., Co-chairs
• Pharmacology: Edward Newman, Ph.D. and Merrill Egorin, M.D., Co-chairs
• PI3K, AKT, mTOR: Afshin Dowlati, M.D. and Lillian Siu, M.D., Co-chairs
• Signal Transduction: Razelle Kurzrock, M.D. and Dan Sullivan, M.D., Co-chairs

Working Groups

• Conflict of Interest and Confidentiality: Joseph Sparano, M.D. and Sherry Ansher, Ph.D., Co-chairs
• Metrics: Deborah Collyar and Anthony Murgo, M.D., Co-chairs
• Scientific Meeting Planning: John Wright, M.D. and Michael Carducci, M.D., Co-chairs

Related Documents

• Public Summary, Investigational Drug Steering Committee, Friday, July 24th 2009
• A clinical development plan is prepared when NCI decides to study an investigational agent. The plan describes the drug's mechanism of action, disease(s) being targeted, patient characteristics, dose and schedule of the drug, phase(s) of the trial and whether single agent, combination, or additional preclinical studies are sought. The IDSC provided input into Clinical Trials Evaluation Program's (CTEP) clinical development plans for these agents: Interleukin-12, GDC-0449, SCH 727965 (CTEP's solicitations for letters of intent for these agents and others).
• Novel Designs and End Points for Phase II Clinical Trials Meeting Summary (Jan 7, 2007)

CCCT Contact: LeeAnn Jensen, Ph.D.